C WorldWide Group’s Zevra Therapeutics ZVRA Stock Holding History

C WorldWide Group’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,000	Closed	-$2.6M	–	137
2018 Q2	$2.6M	Buy	25,000 +770	+3%	+$75.2K	0.04%	88
2018 Q1	$3.06M	Sell	24,230 -2,991	-11%	-$289K	0.05%	70
2017 Q4	$1.76M	Hold	27,221	–	–	0.03%	92
2017 Q3	$1.61M	Buy	27,221 +3,365	+14%	+$179K	0.02%	100
2017 Q2	$1.53M	Buy	23,856 +12,500	+110%	+$823K	0.02%	101
2017 Q1	$890K	Buy	11,356 +1,043	+10%	+$63.4K	0.02%	105
2016 Q4	$487K	Hold	10,313	–	–	0.01%	108
2016 Q3	$741K	Hold	10,313	–	–	0.01%	111
2016 Q2	$657K	Hold	10,313	–	–	0.01%	103
2016 Q1	$2.39M	Hold	10,313	–	–	0.05%	63
2015 Q4	$3.28M	Hold	10,313	–	–	0.06%	68
2015 Q3	$3.2M	Buy	+10,313	New	+$3.16M	0.05%	72

Other funds holding ZVRA

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

C WorldWide Group's ZVRA Position: Q3 2018 in Review

C WorldWide Group sold out of Zevra Therapeutics (ZVRA) in Q3 2018, closing a stake of 25,000 shares — an estimated $2.6M sold.

C WorldWide Group first reported a position in ZVRA in Q3 2015 and held it in 12 quarters. The position peaked at $3.28M in Q4 2015. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2018.

C WorldWide Group reported no remaining Zevra Therapeutics position as of Q3 2018 after selling out during the quarter.
C WorldWide Group sold 25,000 Zevra Therapeutics shares in Q3 2018, an estimated $2.6M.
C WorldWide Group first reported a position in Zevra Therapeutics in Q3 2015 and held it in 12 quarters.
C WorldWide Group's Zevra Therapeutics position peaked at $3.28M in Q4 2015.
33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2018.

Based on C WorldWide Group's 13F filing for Q3 2018, filed 5 Nov 2018.